Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Estrogen Receptor
100%
Apoptosis Induction
100%
Raloxifene
100%
Proliferation Inhibition
100%
Inhibit Growth
100%
Urothelial Carcinoma Cells
100%
Bladder Cancer
37%
Antiestrogen
37%
Growth Inhibition
25%
Poly(ADP-ribose) Polymerase
25%
S-phase Kinase-associated Protein 2 (Skp2)
25%
Disease Stage
12%
Apoptosis
12%
Treatment Outcome
12%
Cell Proliferation
12%
Cancer Types
12%
Cyclin D1 (CCND1)
12%
B Cells
12%
Most Common Form
12%
Caspase-3
12%
Estrogen Receptor-positive
12%
Chemotherapy Alone
12%
Cell Cycle Genes
12%
Induced Growth
12%
Cell Cycle Regulators
12%
Surgical Therapy
12%
Bladder Cancer Cell Lines
12%
Multiple Mechanisms
12%
Cell Translocation
12%
4-hydroxytamoxifen
12%
ICI 182,780
12%
Urinary System Tumors
12%
BTG2
12%
High Recurrence Rate
12%
Estrogens/oestrogens
12%
P27 Protein
12%
Pharmacology, Toxicology and Pharmaceutical Science
Estrogen Receptor
100%
Raloxifene
100%
Transitional Cell Carcinoma
100%
Bladder Cancer
44%
Antiestrogen
33%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
22%
Diseases
11%
Malignant Neoplasm
11%
Caspase 3
11%
Receptor
11%
Recurrence Risk
11%
Cyclin D1
11%
Protein P27
11%
Afimoxifene
11%
S Phase Kinase Associated Protein
11%
Chemotherapy Regimen
11%